Next Article in Journal
HGF/Met Signaling in Cancer Invasion: The Impact on Cytoskeleton Remodeling
Previous Article in Journal
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Previous Article in Special Issue
AR Signaling and the PI3K Pathway in Prostate Cancer
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessBrief Report
Cancers 2017, 9(5), 43; doi:10.3390/cancers9050043

Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma

Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chiba 260-8670, Japan
Department of General Surgery, The First Hospital of Hebei Medical University, Donggang Road No. 89, Shijiazhuang 050031, China
Author to whom correspondence should be addressed.
Academic Editor: Emmanuel S. Antonarakis
Received: 27 February 2017 / Revised: 2 May 2017 / Accepted: 3 May 2017 / Published: 5 May 2017
(This article belongs to the Special Issue AR Signaling in Human Malignancies: Prostate Cancer and Beyond)
View Full-Text   |   Download PDF [380 KB, uploaded 5 May 2017]   |  


Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis. Sorafenib is the only approved systemic chemotherapeutic drug for patients with advanced HCC. Previous studies have shown that androgen and androgen receptor (AR) are involved in human hepatocarcinogenesis and the development of HCC. Here, we discuss the recent data on AR and HCC, and the combination of sorafenib and inhibitors of AR for advanced-HCC patients. Androgen-dependent and androgen-independent AR activation exist in human hepatocarcinogenesis. AR could directly control hepatocarcinogenesis and regulate the innate immune system to influence HCC progression. Combination of sorafenib with AR inhibitors might represent a potential treatment for patients with advanced HCC. View Full-Text
Keywords: androgen receptor; hepatocellular carcinoma; sorafenib androgen receptor; hepatocellular carcinoma; sorafenib

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kanda, T.; Takahashi, K.; Nakamura, M.; Nakamoto, S.; Wu, S.; Haga, Y.; Sasaki, R.; Jiang, X.; Yokosuka, O. Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma. Cancers 2017, 9, 43.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top